[
  {
    "ts": null,
    "headline": "Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma",
    "summary": "Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results from the safety lead-in portion of the confirmatory Phase 3 OLYMPIA-1 trial Primary analysis from an expansion cohort of the ELM-1 trial highlighted continued efficacy and durability in diffuse large B-cell lymphoma patients whose disease had progressed after CAR-T therapy First results from the ELM-2 trial in marginal zone lymphoma demonstr",
    "url": "https://finnhub.io/api/news?id=0091dfaea825af6da5b94b6b878248817b0f4c6b1658cdf1e69668ef4fa95738",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733784300,
      "headline": "Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma",
      "id": 131892749,
      "image": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results from the safety lead-in portion of the confirmatory Phase 3 OLYMPIA-1 trial Primary analysis from an expansion cohort of the ELM-1 trial highlighted continued efficacy and durability in diffuse large B-cell lymphoma patients whose disease had progressed after CAR-T therapy First results from the ELM-2 trial in marginal zone lymphoma demonstr",
      "url": "https://finnhub.io/api/news?id=0091dfaea825af6da5b94b6b878248817b0f4c6b1658cdf1e69668ef4fa95738"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=f7b85bde19c20455de24f00c229e5692505762476a87c3a36adc8c636daf9b09",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733762700,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains",
      "id": 131879509,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=f7b85bde19c20455de24f00c229e5692505762476a87c3a36adc8c636daf9b09"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals - Novel Combination of Pozelimab and Cemdisiran Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab",
    "summary": "TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced positive updated Phase 3 data of an exploratory cohort from the ACCESS-1 trial investigating its first-in-class pozelimab and cemdisiran ...",
    "url": "https://finnhub.io/api/news?id=856f0fd1a03dfda49a2eba7f92bb2e78be539ced967b850db0ed72d3e7076413",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733736376,
      "headline": "Regeneron Pharmaceuticals - Novel Combination of Pozelimab and Cemdisiran Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab",
      "id": 131869368,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced positive updated Phase 3 data of an exploratory cohort from the ACCESS-1 trial investigating its first-in-class pozelimab and cemdisiran ...",
      "url": "https://finnhub.io/api/news?id=856f0fd1a03dfda49a2eba7f92bb2e78be539ced967b850db0ed72d3e7076413"
    }
  }
]